Zanubrutinib with del(17p) in treatment-naive CLL/SLL - Dr. Brian Koffman

Описание: Zanubrutinib, a newer BTK inhibitor (BTKi), showed 60-month progression-free survival (PFS) in frontline high-risk CLL/SLL patients with del(17p) of greater than 72%. This was only slightly less than the 76% PFS seen in lower-risk chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL) without del(17p), proving that in the modern era of targeted therapies, what used to be poor prognostic markers are much less significant.

Dr. Constantine Tam from Alfred Hospital and Monash University, Melbourne, VIC, Australia, and his international colleagues presented the results of one cohort of the SEQUIOA trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025.

Read the full article on CLL Society's website at: https://cllsociety.org/2025/06/zanubr...
__________________________________________________________________________________________
CLL Society Website: https://cllsociety.org/
Facebook:   / cllsociety  
Twitter:   / cllsociety  
LinkedIn:   / cll-society